scholarly journals 59 Fetal Alcohol Spectrum Disorder in Canada’s Children: Pediatric Advocacy for Optimal Physical and Mental Health

2020 ◽  
Vol 25 (Supplement_2) ◽  
pp. e24-e25
Author(s):  
Jocelynn Cook ◽  
Ana Hanlon-Dearman ◽  
Kathy Unsworth

Abstract Introduction/Background Fetal Alcohol Spectrum Disorder (FASD) is a diagnostic term used to describe the range of physical and neurobehavioural effects that may result from prenatal exposure to alcohol. With school prevalence figures of approximately 4%, this may represent as many as 224,000 children across Canada. The pediatrician is key to identifying children who may be at risk based on exposure and in providing regular health and developmental surveillance to families caring for these children. To date, information about the range of specific co-morbidities in the paediatric population has not been clearly established for the Canadian population. The Canadian National FASD Dataform has been collecting diagnostic and assessment data from specialty FASD clinics across Canada for the last 6 years. Objectives The purpose of this abstract is to describe the physical and mental health conditions seen in children and adolescents with FASD in Canada. Design/Methods The Canadian National Dataform collects information from 29 Canadian FASD diagnostic clinics. Dataform started in 2011 as a project funded by the Public Health Agency of Canada to provide national clinical information on FASD in Canada. The database is hosted on the RedCap platform. De-identified clinical data collected includes information on FASD diagnoses, other prenatal exposures, brain domains of impairment and physical/mental health co-morbidities. Descriptive and quantitative analyses were used to compare individuals with and without FASD in the sample. Results Of the 1,684 records in the database, 58% had FASD, 11% were designated as At Risk for FASD and 31% did not receive an FASD-related diagnosis. Nine percent (N=152) were between the ages of 0-5 years, 46% (N=780) were 6-12 years and 24% (N=402) were 13-17 years of age. Of all individuals with FASD, 53% were also exposed prenatally to other substances including nicotine (43%), cannabis (29%) and cocaine/crack (18%), which did not significantly differ from the exposures of those who do not have FASD in the sample. Eighty-eight percent of the sample had confirmed prenatal alcohol exposure (PAE). Data show that children and adolescents across all age groups who meet criteria for FASD had significantly more impairment across each of the 10 brain domains measured when compared to those who have PAE but do not meet criteria for an-FASD diagnosis (Figure 1). The children and adolescents with FASD had significantly higher physical and mental health co-morbidities across all age cohorts (Tables 1 and 2). It is important to note that, in most cases, the rates of co-morbidities are higher than in the general Canadian population. Conclusion Children with FASD/PAE are at risk for physical and mental health co-morbidity and on-going risk for developing new and significant health challenges. They should be followed by a community pediatrician. Appropriate anticipatory guidance should be provided to families at check-ups, including referrals for early intervention. A community team to support families caring for complex children optimizes developmental outcomes, reducing the burden of care. Understanding complexities of PAE changes how we consider public health policy/service delivery.

2018 ◽  
Vol 96 (2) ◽  
pp. 198-203 ◽  
Author(s):  
Erin M. Goldberg ◽  
Michel Aliani

Fetal alcohol spectrum disorder (FASD) is a major public health issue that encompass an array of physical, neurological, and behavioral effects due to alcohol consumption during pregnancy. The classical biomarkers of FASD that are currently used lack sensitivity and specificity, and as such there is an opportunity through the use of novel metabolomics analysis to identify new biomarkers to identify those at risk for FASD, which could more effectively aid in early intervention. The focus of this minireview is to identify current work that is being done in the field of metabolomics in FASD in utero, and to highlight promising metabolites that could act as biomarkers in the future. We will conclude with suggestions for further research, as there is a large gap of knowledge in this particular area of metabolomics.


2018 ◽  
Vol 22 (7) ◽  
pp. 462-469 ◽  
Author(s):  
Sabrina Agnihotri ◽  
Sivaniya Subramaniapillai ◽  
Michelle Keightley ◽  
Carmen Rasmussen ◽  
Debra Cameron ◽  
...  

2021 ◽  
Vol 219 ◽  
pp. 108487
Author(s):  
Svetlana Popova ◽  
Valerie Temple ◽  
Danijela Dozet ◽  
Graham O'Hanlon ◽  
Caitlin Toews ◽  
...  

BMJ Open ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. e046071
Author(s):  
Jocelynn Cook ◽  
Kathy Unsworth ◽  
Katherine Flannigan

IntroductionFetal alcohol spectrum disorder (FASD) is one of the most common neurodevelopmental disorders in North America. It is a complex disability, associated with challenges in cognitive, behavioural and socialemotional functioning, as well as an increased risk of physical and mental health comorbidities, and difficulties in daily living across the lifespan. Previous attempts to characterise the profile of this population have been hampered by differences in data collected across studies, regional discrepancies in terminology and definitions, and a lack of tools to integrate comprehensive datasets.Methods and analysisThe goals of this study are to use the Canadian National FASD Database, a national repository of FASD assessment-related information, to better understand the functional profile, comorbidities, intervention needs and difficulties in daily living experienced by individuals assessed for FASD across the lifespan. We will also examine what factors may be the most sensitive predictors of receiving an FASD diagnosis. Data will be analysed from over 3500 records collected between 2010 and 2021 (ongoing) from 26 FASD diagnostic clinics in seven provinces and territories. Data collection is ongoing, and analysis will be performed on a biannual basis to continue to hone our understanding of the profiles, needs and outcomes of individuals assessed for FASD in Canada. This research is critical for refining FASD assessment and diagnostic practice, enabling accurate and early identification of individuals with FASD, and connecting individuals with FASD and their families to comprehensive and effective services and resources to support healthy developmental trajectories.Ethics and disseminationEthics approval for the National FASD Database Project was obtained from the Ottawa Health Science Network Research Ethics Board. As new knowledge is gained from this project, findings will be disseminated through publications, presentations and feedback to participating clinics, with the ultimate goal of informing FASD research, practice and policy.


Sign in / Sign up

Export Citation Format

Share Document